Marvel Biosciences Corp. and its wholly owned subsidiary Marvel Biotechnology Inc. have reported promising results from a recent study of MB-204 in the Oprm1 mouse model of autism, showing that just 1 hour after administering a single oral dose of MB-204, the drug successfully reversed the social behavior deficits typically seen in the model.